26/03/2020
Marie Skłodowska-Curie Actions

MSCA-IF: Joint application at the University of Granada. Department of Physiology.


  • OFFER DEADLINE
    01/07/2020 12:30 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    H2020 / Marie Skłodowska-Curie Actions
  • LOCATION
    Spain, Granada
  • ORGANISATION/COMPANY
    International Research Projects Office
  • DEPARTMENT
    Promotion and Advisory Unit
  • LABORATORY
    NA

Professor Germaine Escames, from the Department of Physiology at the University of Granada, welcomes postdoctoral candidates interested in applying for a Marie Skłodowska-Curie Individual Fellowships (MSCA-IF) in 2020 at this University. Please note that applicants must comply with the Mobility Rule (more information: http://sl.ugr.es/0aNV).

Brief description of the institution:

The University of Granada (UGR), founded in 1531, is one of the largest and most important universities in Spain. The UGR has been awarded with the "Human Resources Excellence in Research (HRS4R)", which reflects the UGR’s commitment to continuously improve its human resource policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The UGR is also a leading institution in research, located in the top 5/10 of Spanish universities by a variety of ranking criteria, such as national R&D projects, fellowships awarded, publications, or international funding.

UGR is one of the few Spanish Universities listed in the Shanghai Top 500 ranking (http://sl.ugr.es/0aw0). The Academic Ranking of World Universities (ARWU) places the UGR in 268th position in the world and as the 4th highest ranked University in Spain, reaffirming its position as an institution at the forefront of national and international research. From the perspective of specialist areas in the ARWU rankings, the UGR is outstanding in Documentation (ranked in the 36th in the world) or Food science technology (ranked 37th in the world), Mathematics and Computer Science (ranked among the top 76-100 in the world).

The UGR has 4 researchers at the top of the Highly Cited Researchers (HCR) list in the Computer Science area. With regard to broader subject fields, the UGR is ranked in 45th position in the universities worldwide in the discipline of Engineering. It is also well recognized for its web presence (http://sl.ugr.es/0a6i) taking 36th place in the top 200 Universities in Europe. Internationally, we bet decidedly by our participation in the calls of the Framework Programme of the European Union. For the duration of the last two Framework Programmes, the UGR has obtained a total of 66 projects, with total funding of 18.02 million euros, and for H2020, 80 projects with total funding around 20.6 million euros.

Brief description of the Centre/Research Group

Our Research Group is consolidated by the Ministry of Education of the Junta de Andalucía CTS-101: Intercell Communication. We have developed our research for the last 30 years in the Department of Physiology of the Faculty of Medicine at the University of Granada, where we were studied the antioxidant effects of melatonin and the identification of the mitochondria as the main target of melatonin; its ability to delay aging and neurodegenerative pathologies; its anti-inflammatory activity against the innate immune response, among others. Recently, our activity has focused on studies of the oncostatic activity of melatonin, and on the adverse effects of radio and chemotherapy. All these studies have been financed with national, regional and local R + D + I grants, as well as different contracts with companies. All the published articles, books and book chapters, as well as the various communications to international and national congresses, have been widely accepted by the scientific community. Through the Fundación Empresa-Universidad we have set up a free radical laboratory in which techniques related to the determination of oxidative stress markers are carried out. We have four international patents on melatonin in the last five years: one of them (number PCT / ES2012 / 070728) has been transferred to a pharmaceutical company. It is melatonin gel for the prevention and treatment of mucositis and is currently under a multicenter clinical trial (EudraCT nº: 2015-001534-13); The other two patents (number = PCT / ES2012 / 070349 and PCT / ES2015 / 070236), in collaboration with a pharmaceutical company, are also under clinical trial (EudraCT no: 2008-006782-83).

Project description

Intracellular reduction of antineoplastic drugs is a very frequent mechanism that confers chemoresistance. This mechanism has been related to the expression of a series of proteins, with the P-glycoprotein (P-gp) being the best known. Furthermore, these expulsion pumps are ATP-dependent, so an inhibition of ATP synthesis could inhibit the function of these transporters. This research group has shown that melatonin increases mitochondrial function and ROS production in tumor cells. Our hypothesis proposes that this increase in oxidative stress would inhibit ATP synthesis, blocking the function of the P-gp protein and, in turn, decreasing resistance to antitumor treatments. The main objective of our study is to investigate the link between P-gp protein and mitochondrial function, and to relate these effects to the mechanisms of resistance to onostatic treatments. In turn, evaluate the effects of different melatonin formulations, using nanobiotechnology, to increase the bioavailability of melatonin in the tumor. To do this, the connection between mitochondrial function, oxidative stress and chemoresistance in NCI / RES-ADR chemoresistant tumor cells treated with melatonin will be studied. The effects of melatonin on SCC-9 cells genetically engineered for the ABCB1 gene will be evaluated using CRISPR / Cas9 technology. The effects of different melatonin formulations will be evaluated in mice with MCF-7 and NCI / ADR-RES xenografts, as well as primary cultures. The effects of the most effective formulations will be evaluated in mice with xenografts from other cell lines. The mitochondrial pathway will be analyzed (ROS, NAD + / NADH, respiration, membrane potential, pyruvate, ATP, respiratory complexes, ME of mitochondria), P-gp, viability and apoptosis. In vivo, the evolution of the tumor will be followed by NMR and IVIS Spectrum

Research Area

Life Sciences (LIFE)

For a correct evaluation of your candidature, please send the documents below to Professor Germaine Escames (gescames@ugr.es):

  • CV
  • Letter of recommendation (optional)

Disclaimer:

The responsibility for the hosting offers published on this website, including the hosting description, lies entirely with the publishing institutions. The application is handled uniquely by the employer, who is also fully responsible for the recruitment and selection processes.